impact of recession on your business
Prostate Health Market

Prostate health market Size, Share & Segment by Disease Indication (Prostate Cancer (AR Directed Therapies, Hormone ADT, Cytotoxic Agents, PARP Inhibitors), Benign Prostate Hyperplasia (Alpha Blockers, 5 Alpha Reductase), Prostatitis (Prescription, Over the counter), by Regions and Global Forecast 2022-2028

Report Id: SNS/HC/2241 | July 2022 | Region: Global | 127 Pages

Prostate Health Market Overview:

The Prostate Health Market Size was valued at USD 31.3 billion in 2021, and expected to reach USD 56.5 billion by 2028, and grow at a CAGR of 8.8% over the forecast period 2022-2028.

An organ of the male reproductive system is the prostate gland. Benign prostatic hyperplasia, also known as BPH, is a benign enlargement of the prostate that is the third most prevalent type of prostate illness after inflammation (prostatitis). Men are said to be affected by the condition known as benign prostatic hyperplasia (BPH). It involves non-cancerous prostate gland hypertrophy. The likelihood of developing BPH rises with age, even though it rarely manifests symptoms before the age of 42. Up to 91% of males over the age of 80 and over 50% of men between the ages of 52 and 62 are affected by the disorder. Patients with BPH have received treatment through the use of drugs and surgery.

Prostate Health Market

MARKET DYNAMICS

DRIVERS

  • Expanding obesity
  • Grants, investments, and cash for BPH therapy research
  • Increasing prostate cancer incidence
  • Rising need for hormone treatment medications
  • Novel treatments for prostate cancer

RESTRAINTS

  • The negative effects of BPH medicine

OPPORTUNITIES

  • Newer markets

  • Favourable product pipeline

CHALLENGES

  • Men's knowledge of prostate health is lacking

  • Prostate health market recalls of products

IMPACT OF COVID-19

The prostate health market experienced a decline in sales, and the pattern persisted through the end of December 2020. The development of this industry is being constrained by unfavorable changes in legislation and standards. Major regulatory bodies from all around the world, including the CDC, WHO, MHRA, TGA, and EMA, have determined that people with cancer are more likely to get COVID-19 infection than healthy adults. So, at hospitals and cancer treatment facilities, screening, diagnostic tests, and surgical procedures are severely limited or delayed. Market upheavals in the field of prostate health are anticipated as a result. Hospitals and caregivers might expect delays in screening procedures and elective surgery as a result of the aforementioned issues.

By Disease Indication

In the global market, the prostate cancer sector is predicted to account for the biggest revenue share. Hormone therapy is typically a successful first-line cancer treatment strategy. Alternatives to hormonal therapy include chemotherapies, radiopharmaceuticals, cancer vaccinations, and follow-up hormone therapies. Within a few months, cancerous cells develop resistance to these medications. As a result, over the course of the projected period, immunotherapies are expected to be extensively used for cancer treatment.

COMPETITIVE LANDSCAPE

Some of the major key players are as follows: Astellas Pharma, Eli lilly and Company, Glaxo smithkline, Abbott Laboratories, Eli Lilly and Company, Abbvie, JOHNSON & JOHNSON SERVICES, INC., AstraZeneca, Merck, SANOFI, Pfizer inc, and other players.

MARKET SEGMENTS:

By Disease Indication

  • Prostate Cancer

    • AR Directed Therapies

    • Hormone ADT

    • Cytotoxic Agents

    • PARP Inhibitors

  • Benign Prostate Hyperplasia

    • Alpha Blockers

    • 5 Alpha Reductase

  • Prostatitis

    • Prescription

    • Over the counter

Prostate Health Market

REGIONAL ANALYSIS

Among the pioneers in the field of health care, North America was developing bladder supplements. The US market increase, which has a major impact on North America's prostate health market, can be attributed primarily to targeted population growth, high incidence of BPH, prostate cancer, prostatitis, and an increase in medical equipment. manufacturers. The expansion of this market is fueled by lucrative refund policies, high losses, strong health care infrastructure, research funding, and new releases.

REGIONAL COVERAGE

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Prostate Health Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 31.3 Billion
Market Size by 2028 US$ 56.5 Billion
CAGR CAGR of 8.8% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Disease Indication (Prostate Cancer (AR Directed Therapies, Hormone ADT, Cytotoxic Agents, PARP Inhibitors), Benign Prostate Hyperplasia (Alpha Blockers, 5 Alpha Reductase), Prostatitis (Prescription, Over the counter)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Astellas Pharma, Eli lilly and Company, Glaxo smithkline, Abbott Laboratories, Eli Lilly and Company, Abbvie, JOHNSON & JOHNSON SERVICES, INC., AstraZeneca, Merck, SANOFI, Pfizer inc, and other players.
Key Drivers • Expanding obesity
• Grants, investments, and cash for BPH therapy research
• Increasing prostate cancer incidence
Restraints • The negative effects of BPH medicine


Frequently Asked Questions (FAQ) :


Table of Contents

 

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

4.2 Impact of Ukraine ware

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. Prostate health market Segmentation, By Disease Indication

8.1 Prostate Cancer

8.1.2 AR Directed Therapies

8.1.3 Hormone ADT

8.1.4 Cytotoxic Agents

8.1.5 PARP Inhibitors

8.2 Benign Prostate Hyperplasia

8.2.1 Alpha Blockers

8.2.2 5 Alpha Reductase

8.3 Prostatitis

8.3.1 Prescription

8.3.2 Over the counter

 

9. Regional Analysis

9.1 Introduction

9.2 North America

9.2.1 USA

9.2.2 Canada

9.2.3 Mexico

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Italy

9.3.5 Spain

9.3.6 The Netherlands

9.3.7 Rest of Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 South Korea

9.4.3 China

9.4.4 India

9.4.5 Australia

9.4.6 Rest of Asia-Pacific

9.5 The Middle East & Africa

9.5.1 Israel

9.5.2 UAE

9.5.3 South Africa

9.5.4 Rest

9.6 Latin America

9.6.1 Brazil

9.6.2 Argentina

9.6.3 Rest of Latin America

 

 

10.Company Profiles

10.1 Astellas Pharma

              10.1.1 Financial

10.1.2 Products/ Services Offered

10.1.3 SWOT Analysis

10.1.4 The SNS view

10.2 Eli lilly and Company

10.3 Glaxo smithkline

10.4 Abbott Laboratories,

10.5 Abbvie

10.6 JOHNSON & JOHNSON SERVICES, INC.

10.7 AstraZeneca

10.8 Merck

10.9 SANOFI

10.10 Pfizer, inc.

 

11.1 Competitive Benchmark

11.2 Market Share analysis

11.3 Recent Developments

 

12.Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of the good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.